-
2024-519578-38-00
10
2026-03-30
Classic congenital adrenal hyperplasia
-
2025-521352-38-00
5
2026-01-16
Hereditary Angioedema
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2025-521658-40-00
1
2025-10-27
Atopic dermatitis
-
2024-519795-11-00
4
2025-10-06
Atopic Dermatitis
-
2024-519496-26-00
10
2025-09-25
Intestinal Failure
-
2024-516790-78-00
4
2025-09-04
stage IV NSCLC (non-small-cell lung cancer)
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-518839-11-00
4
2025-08-25
Stage IV Squamous Non-Small Cell Lung Cancer
-
2024-519551-29-00
5
2025-08-21
Acute cerebral ischemic stroke
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2024-511458-32-00
5
2025-06-15
Ulcerative colitis
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-517032-22-00
5
2025-06-10
Immune system diseases.
-
2023-509370-39-00
5
2025-06-03
connective tissue diseases
-
2023-505946-24-00
5
2025-05-15
Primary Immunodeficiency Diseases
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-511346-39-00
3
2025-03-28
Immune-mediated necrotizing myopathy
-
2024-515702-63-00
5
2025-02-20
Moderate-to-Severe Active Thyroid Eye Disease
-
2023-509434-19-00
5
2025-02-10
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)